Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai Applies for SEP-190 for Insomnia
December 13, 2010
- Acotiamide to Drive Zeria's Global Business
December 13, 2010
- Early Price Settlement Unlikely: Mr Minari of Nihon Chouzai
December 13, 2010
- Kyowa Hakko Bio's Hofu Facility Complies with GMP Requirements: Korosho
December 13, 2010
- Teijin to Extend Pharma Business by Launching Feburic, Synvisc: Mr Ohyagi
December 13, 2010
- Qol to Open More Convenience Stores with Dispensing Services
December 13, 2010
- Ranbaxy Launches Generic Aricept in the US
December 13, 2010
- Blopress Returns to Top Place in 3rd Qtr: IMS Japan
December 13, 2010
- M3 Acquires EMS Research in the UK
December 13, 2010
- Hospira Japan Launches Its 1st In-house Oncology Generics
December 13, 2010
- Astellas Obtains Oncology Technology Platform from AVEO
December 13, 2010
- Itochu, PRISM BioLab to Market Library of Chemical Compounds
December 13, 2010
- Generics Should Be Priced at Lower Levels in Japan: Dr Eiki of Bayer Yakuhin
December 13, 2010
- Sawai to Re-Propose Merger to Kyorin
December 13, 2010
- Bayer, Regeneron to Apply for VEGF Trap-Eye in Europe, US in 2011
December 13, 2010
- Eisai to Donate Antifilarial Drug through WHO
December 13, 2010
- Global Players Accelerate Personnel Downsizing
December 13, 2010
- Takeda to Apply for Hematide in US in 2Q 2011
December 13, 2010
- “Vaccine Gap” in Japan Needs Immediate Resolution: Prof. Plotkin
December 13, 2010
- Develop More Drugs for Cancer, Hereditary Diseases: Mr Inoue
December 13, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…